Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Misha V. Blagosklonny subsequently
Moved to the USA, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Various biomedical themes, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
Trial publication.
 
After authoring seven papers within the period of a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published dozens of experimental research papers and theoretical papers as lead
Writer. These sole-author articles
Encompassed two important topics.
The first of these explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Verifying their resistance. The results and underlying
Concept were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the paper was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
 
The second topic throughout Dr. Blagosklonny’s sole-author publications
Is a research methodology to develop knowledge via
Bringing several facts together from seemingly irrelevant areas.
This results in new notions with testable predictions, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant outcome revealed by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others cannot even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Preventing organism aging — in other words, “preventing cancer
By staying young. ” His laboratory closely worked together with
Andrei Gudkov’s and finalized research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Drugs besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including a few models like
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the prevention of cellular
Senescence via rapamycin and other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging medications to be taken by humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.